Table 3 Mean doses to the spared salivary glands and oral cavity by primary tumor site
Tumor site | Patients (nb) | Ipsilateral PG | Contralateral PG | Ipsilateral SMG | Contralateral SMG | OC | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of spared glands | Mean dose Gy (range) | No. of spared glands | Mean dose Gy (range) | No. of spared glands | Mean dose Gy (range) | No. of spared glands | Mean dose Gy (range) | Nb | Mean dose Gy (range) | ||
Oral cavity | 8 | 5 | 31 (29.4-32.5) | 8 | 27.1 (16–31.7) | NS | NA | NS | NA | NS | NA |
Oropharynx | 31 | 12 | 28.6 (25–31.5) | 30 | 27.5 (23.6-32.2) | 2 | 35.5 (33–38) | 8 | 33.8 (29–36.5) | 5 | 34.2 (29.7-38.2) |
Hypopharynx | 17 | 9 | 28.9 (24.4-31.5) | 17 | 27.6 (22.9-34.4) | 1 | 39.6 | 4 | 36.1 (28.7-39.5) | 9 | 34.8 (30.5-40) |
Larynx | 10 | 9 | 26.8 (20.7-33.2) | 10 | 25 (19.1-30.1) | 1 | 34.9 | 3 | 36.7 (34–39) | 9 | 30.5 (23–39.7) |
Nasopharynx | 3 | 2 | 30.2 (30.4-30) | 3 | 27.8 (26.7-28.7) | 1 | 38 | 2 | 33.1 (30.3-35.8) | 3 | 33.5 (29.7-35.2) |
Unknown primary | 1 | 1 | 32.5 | 1 | 17.3 | NS | NA | 1 | 28 | 1 | 44.3 |